Yes, but with a review process built into the publishing cadence, since every post, reply and image needs to be approvable the same way any other regulated content is.
Social media itself is not restricted; what is restricted is what can be said in a post, the same claims rules that apply everywhere else. The practical problem most pharma companies hit is not permission, it is a publishing cadence built for a consumer brand colliding with a medical review process it was never designed to accommodate.
Corporate visibility, disease awareness, employer branding and — depending on category — consumer health content all run successfully on social media once the cadence is sized to what medical review can actually sustain. See pharmaceutical social media management for how we build that cadence deliberately rather than defaulting to daily posting.
The other real constraint is community management: comments and messages can contain clinical questions that should never be answered by whoever runs the account. A documented policy routing anything clinical to your medical team, agreed before the channel goes live, is what makes this safe.
Whatever your medical review process can sustain, which for most pharmaceutical organisations is less frequent than a consumer brand, and that pace is the right choice rather than a shortfall. Consistency matters more than volume, since a thin but reliably reviewed cadence builds more trust with both patients and HCPs than frequent unreviewed posts.
Yes, within the same category and platform restrictions that apply to any paid pharmaceutical media, including claim substantiation and, on some platforms, advertiser certification. See pharmaceutical paid media for how those restrictions apply across channels and how a campaign is typically structured to stay within them.
Usually LinkedIn for a pharmaceutical company, since its professional audience and lighter restrictions on non-promotional content make it the most sustainable channel to maintain consistently. See LinkedIn management for how that presence is typically resourced and reviewed on an ongoing basis rather than as a one-off campaign.
A named team member should review comments daily, since patient comments describing side effects can trigger adverse event reporting obligations regardless of platform. Most organisations pair this with a documented escalation path to pharmacovigilance, plus moderation settings that hold comments for review before they appear publicly wherever the platform allows it.
Tell us your review process and we will tell you what a sustainable social media cadence looks like.